Access
To read this story in full you will need to login or make a payment (see right).
Article
Nature Medicine 10, 1352 - 1358 (2004)
Published online: 21 November 2004 | doi:10.1038/nm1138
Prevention of cholesterol gallstone disease by FXR agonists in a mouse model
Antonio Moschetta1, Angie L Bookout1 & David J Mangelsdorf1
Abstract
Cholesterol gallstone disease is characterized by several events, including cholesterol precipitation in bile, increased bile salt hydrophobicity and gallbladder inflammation. Here, we describe the same phenotype in mice lacking the bile acid receptor, FXR. Furthermore, in susceptible wild-type mice that recapitulate human cholesterol gallstone disease, treatment with a synthetic FXR agonist prevented sequelae of the disease. These effects were mediated by FXR-dependent increases in biliary bile salt and phospholipid concentrations, which restored cholesterol solubility and thereby prevented gallstone formation. Taken together, these results indicate that FXR is a promising therapeutic target for treating or preventing cholesterol gallstone disease.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Chipping away at gallstonesNature Medicine News and Views (01 Dec 2004)
Chipping away at gallstonesNature Medicine News and Views (01 Jul 2008)
See all 3 matches for News And ViewsRESEARCH
Hepatic insulin resistance directly promotes formation of cholesterol gallstonesNature Medicine Letter (01 Jul 2008)
See all 19 matches for Research